Analysts have been eager to weigh in on the Healthcare sector with new ratings on Urogen Pharma (URGN – Research Report) and Akili (AKLI – Research Report).
Urogen Pharma (URGN)
Goldman Sachs analyst Paul Choi maintained a Hold rating on Urogen Pharma today. The company’s shares closed last Tuesday at $11.67.
According to TipRanks.com, Choi is a 5-star analyst with an average return of
Urogen Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $54.00.
See the top stocks recommended by analysts >>
Akili (AKLI)
In a report released today, Rahul Rakhit from LifeSci Capital maintained a Buy rating on Akili. The company’s shares closed last Tuesday at $0.41, close to its 52-week low of $0.33.
According to TipRanks.com, Rakhit is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Akili is a Strong Buy with an average price target of $3.25, implying a 692.7% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on URGN:
